Pre-earnings options volume in Reviva Pharmaceuticals (RVPH) Holdings is normal with calls leading puts 25:1. Implied volatility suggests the market is anticipating a move near 21.1%, or 0c, after results are released. Median move over the past eight quarters is 7.2%.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Largest borrow rate increases among liquid names
- Reviva Pharmaceuticals announces grant of European patent for brilaroxazine
- Reviva Pharmaceuticals’ Brilaroxazine Study: A Potential Game-Changer in Schizophrenia Treatment
- Reviva Pharmaceuticals price target lowered to $4 from $11 at H.C. Wainwright
- Unusually active option classes on open October 23rd